InMed Pharmaceuticals Inc(INM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:00 PM ET (Korea 10/31 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.12 | Insider Own | 15.57% | Shs Outstand | 5.3M | Perf Week | 11.11% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | 105.33% | Shs Float | 4.6M | Perf Month | 18.52% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 36.84% | Short Float | 0.14% | Perf Quarter | 9.59% |
| Income | -0.01B | P/S | 4.53 | EPS this Y | - | Inst Trans | 106.94% | Short Ratio | 0.09 | Perf Half Y | 123.93% |
| Sales | 0.00B | P/B | 7.95 | EPS next 5Y | - | ROA | -122.41% | Short Interest | 0.01M | Perf YTD | 50.94% |
| Book/sh | 0.2 | P/C | 3.94 | EPS past 3/5Y | 63.64% 66.67% | ROE | -157% | 52W High | -31.33% ($2.33) | Perf Year | -13.51% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -1168.44% | 52W Low | 178.26% ($0.57) | Perf 3Y | -84.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 66.05% | Gross Margin | -6.3% | Volatility(W/M) | 7.77% 5.25% | Perf 5Y | -99.79% |
| Dividend TTM | - | EV/Sales | 3.38 | Sales Y/Y TTM | -60.74% | Oper. Margin | -510.84% | ATR (14) | 0.08 | Perf 10Y | -99.93% |
| Dividend Ex-Date | - | Quick Ratio | 1.37 | EPS Q/Q | -60.54% | Profit Margin | -669.61% | RSI (14) | 70.63 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.37 | Sales Q/Q | -100% | SMA20 | 13.6% ($1.41) | Beta | 0.98 | Target Price | $468.78 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/9 | SMA50 | 15.9% ($1.38) | Rel Volume | 0.5 | Prev Close | $1.62 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 33.11% ($1.2) | Avg Volume(3M) | 0.07M | Price | $1.6 |
| IPO | 2008/11/17 | Option/Short | No/Yes | Trades | 102 | Volume | 36,687 | Change | -1.54% |
🧠 A clinical-stage pharmaceutical company developing treatments for Alzheimer's disease and dry eye conditions, targeting CB1/CB2 receptors.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded less than usual. That is 50% of its average volume.
INM has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $453. Peers typically go for $205.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 36.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
LYTE Roundhill Photonics & Optics ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
XLC State Street Communication Services Select Sector SPDR ETF 21.8B 
IGV iShares Expanded Tech-Software Sector ETF 13.9B 
PEJ Invesco Leisure and Entertainment ETF 361M 
GOLS Gabelli Opportunities in Live and Sports ETF 36M 
ODDS Pacer BlueStar Digital Entertainment ETF 3M It ranks #72 of 83 in the industry
Based on market cap of $9M.
OPTH#70 Optimi Health Corp $14M PER - 
BFRI#71 Biofrontera Inc $13M PER - INM#72 InMed Pharmaceuticals Inc $9M PER - 
UPC#73 Universe Pharmaceuticals INC $7M PER - 
SNOA#74 Sonoma Pharmaceuticals Inc $5M PER - 
FAQ
What kind of company is INM?
INM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of INM?
The market cap of INM is approximately $9M, ranking 5,476 within its sector.
What is the 52-week high and low for INM?
INM has recorded a 52-week high of $2.33 and a low of $0.57.
